Clinical Trial Update: High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating high-dose Y-90 ibritumomab tiuxetan added to reduced-intensity allogeneic stem cell transplant for relapsed or refractory aggressive B-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• Y-90 ibritumomab tiuxetan (ibritumomab tiuxetan)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2021-05-25